<SEC-DOCUMENT>0001193125-14-007262.txt : 20140110
<SEC-HEADER>0001193125-14-007262.hdr.sgml : 20140110
<ACCEPTANCE-DATETIME>20140110074536
ACCESSION NUMBER:		0001193125-14-007262
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140110
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140110
DATE AS OF CHANGE:		20140110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		14520212

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d657091d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;10, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GALECTIN THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-31791</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-3562325</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NORCROSS, GA 30071 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (678)&nbsp;620-3186 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8 &#150; OTHER ITEMS</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Items. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;10, 2014, Galectin Therapeutics&nbsp;Inc. (the &#147;Company) issued the attached press release. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;9 &#150; FINANCIAL
STATEMENTS AND EXHIBITS</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Financial Statements of Businesses Acquired. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Pro Forma
Financial Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Shell Company Transactions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Not applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:51.70pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated January 10, 2014</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">Galectin Therapeutics Inc.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: January&nbsp;10, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;/s/ Jack W. Callicutt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Jack W. Callicutt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d657091dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g657091g33g85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Galectin Therapeutics Announces Update on Financing Activities and Cash of $32.3 Million </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Norcross, GA (January 10, 2014) &#150; Galectin Therapeutics Inc. (NASDAQ: GALT)</B>, the leading developer of therapeutics that target galectin proteins
to treat fibrosis and cancer, today announced that it had sold, from October&nbsp;28, 2013 through January&nbsp;9, 2014, a total of 2,391,204 shares of common stock at an average price per share of $9.99 for total gross proceeds of $23,883,137
through its at-the-market (ATM) financing vehicle. The Company entered into an ATM financing arrangement with MLV&nbsp;&amp; Co. LLC (&#147;MLV&#148;) in October 2013, which provides it the opportunity to sell up to $30 million in registered shares
into the open market through MLV from time-to-time under its effective shelf registration. After commissions, the Company received $23,164,712 in net proceeds. The intended use of the net proceeds is to finance the Company&#146;s planned Phase 2
program for GR-MD-02 after completion of the Phase 1 clinical trial and for general corporate purposes. The Company currently has approximately $32.3 million in cash, and there are approximately 20.7&nbsp;million shares of our common stock
outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Galectin Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin
Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company&#146;s unique understanding of galectin proteins, key mediators of biologic function. We are
leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and
commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at <U>www.galectintherapeutics.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains,
in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as
&#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those
described in the statements. These statements include those regarding the anticipated use of proceeds of its cash. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include,
among others, completion of the Phase 1 clinical trial and successful commencement of a Phase 2 trial in the future. Future clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove time consuming and
costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Regardless of the results of current or
future studies, we may be unsuccessful in developing partnerships with other companies or obtaining capital that would allow us to further develop and/or fund any studies or trials. To date, we have incurred operating losses since our inception, and
our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on Form 10-K for the year ended December&nbsp;31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may
cause our views to change, we disclaim any obligation to update forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONTACT: Galectin Therapeutics Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Peter G. Traber, MD, 678-620-3186 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">President, CEO,&nbsp;&amp; CMO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>ir@galectintherapeutics.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g657091g33g85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g657091g33g85.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+0#'`P$1``(1`0,1`?_$`,<````&`@,!````````
M```````&!P@)"@4+`0,$`@$!``$%`0$!``````````````4!`@,$!@@)!Q``
M``8!`@0$!`$'"`8+`````0(#!`4&!Q$(`!(4"2$3%18Q%Q@*(D%188$C)!EQ
MH<$R0E)#)?#1)B<H.9&"DJ*RTC-U-K9W$0`!`P$&`0@%"`<&!P`````!`!$"
M`R$Q$A,$!11!88$B,A4&%E%",P<(<9'!T5)B<B.AL>&"LD,U\/%SM!<X-$1D
M="4F&/_:``P#`0`"$0,1`#\`F5[J_=HS;7MW>&NT5VVS5EWOESV]C&][R[:(
MPD_5-L-*F8]:P.)U2",59G+75G2&CB:.FZ(JVCV!$3"DLX<)E*1.MH'8HV32
M$0RFMY45<.X?G5T@*EMS?NUMUDO;Q]+.03-)#2J'ZVE1<;5D[@O[O'QC,#)I
M%(55=4X"<2+WYHVB99V)8^FLY]LB7LB<9BF#D+-;=@5]NMBN.W_-5+@VIG\_
M7L5*6QQ8+-@'+!8MH92#=P3KT5T[3(U>1JB:PJ%(E/[+.>,E;G^V5M>W`Y?L
M,G:,BY7B<A6RQR\NZ*\><[O+-[2CHLJY46^K.`B4$&#<HD*)4&Q0'Q#7@BE)
M`-?`."("&G@/!%!-]P=C&YN.W'N4W"XRW!;AL%Y&V_XI>6VLCAK+=@H5:LI6
M]DKQI5A>Z]$@1"Q&<1`+((N/-2<-P.`$.``("1+?V(Y:5GNT#L$FYV2?S,S*
MX*8/Y.5E7CB0DI%ZYL=A5</7S]VHJZ=NG"AQ,=10QCF,(B(B/CP12T\$0X(A
MP1#@B\SUXTCF;R1?N$6;"/:N'SYVX.5)NT9M$CKN7*ZAA`J:+=$ACG,/P*`C
MP1%^DW2K9)I]6R!1)UC9J3=H"(M=2LT6H*T98:W.L4)2&F8U4Q2&58R4>Y36
M2.(!S$.`Z<71C&)-67(%<#"-I[1<<UR9W"=P[;=-[Z[!V[V4M:QW&UF@!D22
M8J5)^G3AB/36<TJP;6@R@IGE6L1)(KF`R0-C@<2$4%0!+Q$G>])6W*.VPC+.
M()<^D!R/T+K8^`/$5/P1#QK/AQLT*V`Q$OS.O(1B<+W&1MY>8)]O$HN00X(O
MD?B'Z?C^C3\OZ^+*OLQ^)8YQ$\493PQ$06Z;^FY0V]ZS+>ZS$NW7$:>S.RV*
MNYRR7N0HF+Z^C5HJ#EIRPM;'7;D[5@4V\[&2<<BV7=Q:2RJYDR%020,<Q@`!
M'B)WP:DQ@=).4-03$`Q8F\O85Z1^&'9?=WOOCG4S]Z="E/PGIMOKUJN9+#$Y
M5-XL7`!)L%KDL`]Q/NU'"FY_`E!99.W_`._*W9'MA623JP5H@T6CX6I:SI/F
M"&]1CZM$V&Y/$!U3,NHY1(LIJ";<2AJ+2;7KYP>KKJIJV6``#^W2W0H?WK^\
M/W=;]K:V@]U_A?;-L\/TI2C3U4C4EJI$>N!C$`#80""1<2#<Z**WN;3K9(>U
MXO.%=1D'QRQ[=8PS$&@9=8/+)T<T_CFS!,W-_5.*I2ZZ>/$RV'JDN18OPIR;
M3:2FH[RH#=?A>J2>7\1[E[5*4&/.@M-5:T!232L*S>*E3:OZ[.J0K-*Q,!4/
MJ9N?]]$AOV9E0`0X(HK!WZ;P-1_WYV+XC\(FK:?J_P`A#PX(G0[.-T&Z'-6=
M&&-['G"Q='.TC(0LW98"HOU(J::UMRXA)E..=0@1T@M&R"9#IH.`%!41$J@"
M4=."+'Y/OG?,J]$J<?C"O,<B6NY8-Q5*66ZSV-,51LWB',7NR>L66VC.K,'<
M?!6EJ_H[%M7F#-5)4K"1<)O3F5#G)P15C_ME<H2N]/OW[H=VV2%EI&[6G$&>
M,L,%712J*13BZ7>D5EFR;F,!@1)!U.:]/0Y=`(@3D#0OAP1;),I0(``&OY/$
M?B.@`4/T:Z`'\OQ^/!%]BF<Q?`NH&^(&#4IBC\2F#4-2F#P$/@(<$2);<MO&
M.=J^'JM@K$<?(QF.Z:\M3NO1TF^+(NF`7"WSEUE&A70(-2=$A,V)P5LF"901
M;@0FH\NHD47%4[B>Y#=QOAW2;.-F5!QU2*?LP/$US.6YG<%7KU/Q$QDZ:<.4
MV]`Q3CFIR53]7Z!./<J.I%_,HD%)$3I("FJ@HH1$^4[GFX[:AW'-N?;\WR4G
M"]DA=X\5*&VX;CL"!<*RS/;XMUT"M*R=C"ZRMD<1"Z\D9%ND\CY=PF)GS8>0
M=503(ES[\_\`R=>X9^3_`(=;)X#_`.YP_!%C^PPZ;,NS1V^W;QPBT9M=N\>Z
M=.G*J:+9LW;S-@5<.'"ZAB$;H()%%0QS#RE(0PCIIP1%3;KW!]PO<HMN;938
M!$8:I.U?".0I7$2&Y[.L-=+T[SCDBNH(.;,&(L85&<I*+7'4(#Q`@34G,BN^
M%8HHM"EU'@BZ]M'=*O2G<%R#VL=[%'QUCO='$4MEE#"F0<3RM@7Q%N'QR[CS
MR:B\-#6PJMEI5YBX]HZ5<12[EZFKT+KR5A!$.<B4C>;W.BX4W(8;V$[9<;QV
MXG?9GF.<62%QW*V96H8VPYC6.1>NI?+F<;>RCY>4B*RV8Q;E9I',FBLC(E3#
MR_+!1(RA$@^^+>]W'NVOB&O;FLO8QV^;M\0)Y`JE1RS0=M],RY1,J8^A;8JL
MU0MM3>66R7^,N,;'2A4FBJ3QG&F%1T@85$P,<2D2*_<8[J=YV%.V%D/,^V)[
MC/'^)+U0J/5<E3US0N;;<5#Q^<)1C55X:BP"#`M1KKT(6RII/GC]T+YB<5RH
M(@J4BI2)W?;1EM]K;9ELS2D,>[4%L2--H&(C5<\/E/+!<E2B;3"L(./V<HRE
M\;!58MS-/D6I)-1-ZZ29IJ*F1!;E*0;A(BZY.1C:$QK`G=!W)6/OFQO;UW`[
M(-M.#;XKA:U6NRYDHERD,MY`L=,8T!:\TEC!9$7J5%<>VEG*0)N6;ED8Q%$S
M)E!,2`)M?AZ&:*^".<`SL'MYUL1U>JAHQM\:E0:$2?!B.%_2SLEG[Y?=&WP=
MK#%3//.)-M^`,G8(?VBG4):]W;)=N2ND'<;.TEWPH2&-(:"CFBL$<(91!N^1
MFE3`J<IE$`*(:YEKIT%;W)=PO=QC:"RULZQ=M_POBZR52%GZ+;MX"&47-PRV
MI(P[=^::@L6T,L2_QUCYZ]<>7'O9M\I*OFQ0<^GHI')S$2;=I;NIY"WVW'=M
MMJW&X;K6#-WVR+(B=`S%5Z18WEHQU9&Z\K/P3:UTV1D4DY1LS"8K3A-1NL=;
MF2505(H/F&33I(8@QN=6RA"88@.>7EL4RTM6(&:?0$E+1;*1D*M)KRU<<O44
MU5(>6=1K^$6D&`G`00=FBI1R@!P\036,`#X\6F`E6C7+YD0P^9EM4M7JJ%*I
M1HU)1I5A$3`-XB00/D<!_2JU?<8S=8\F[@+50U'KE"C8FE5:Q!P)%AZ!>;;-
MDBSM@=M@_9+/W#Q4R21S`(I))%`N@B(C>\^24A\BP4Y3IU36$I&J183ZO/'T
M'YUYMN7;^OVY?&OS*K-^IE?BSV&8KOI,^RFEWH+0OD$4<'4:)'0436%<!*4V
MN@!P5')M-I3N;#VT]T]NJU5I%IW(U:;J-)05;U>NR!K4M&QB*ISG$/)%'F=G
M2Y^5$RXJ&03`")B4H:<$1`'M`YA`!_WLXVT#^['60YA`/S%\CQX,38$:1($6
M=Q>G';3NW?D3;QG&O95L&0J78(V(A['&JQ42RFV[]12<BU6""R1GI$VFB)CB
M)@.(ZA\`U\>+'E(X:9!(6M1K5.K2U``K$R!,;GMPV?,]MJEP$FNA^<W,!!#7
MF'0=0_K#XZC^CQXO8W>M]*V6E=ZWTK7`]IW%KOM$?<U77:/D;6!J>6X?*.)L
M3S+LH$8V2I9)Z7)&#Y%LKJ"1TY@U71B1*.@A(D.D/XPT$BV0!1*(:D'4!'7Q
MYAT,/B8-3".H`81TT\`#PX(JIWW.6VRF8LV!9OWL8DO&<,/[BH/(F*GJ]MH&
MX#,=:B;"A9[/#4B6@GM(9WE.F(QZD6[!4A63!N<JZ(*`(B*G,1&'[93;#7;A
ML%P'OARG?<Y99W&WZ<RR[+:LEYYR];8.!AHRY6?'D9"Q-&DKBK2U6OH,6*JB
MCM@X7.[6,J"A1`@%(GOV7N836<=Z&4^W_P!N*AT.[YJQ"0LMNRW(9.3=,\%[
M?S]42%])/`5A:-N&;\LF>)](WCF[I@Q16;J$</N1%<"D4*7=*Q%D#%_>\[!#
M_)^X#(NX&Y6[/#]W*2=JC:E4*;7#1F0,>I)1N-\>5"'8L:C#G%V)EBN'<H]<
MBDGYKI02%'@BGO[]1P#L[=P\1*8/^'BQ@&H!J//+0Q2B`:Z\O,/Q_0/!$P#:
MY*7:&^U(B)/')W:-U8]LC,+N`68`/J"+M&M7SF49\H&T7*S,L)1#\0"`<$38
M/M=]G^U#/W:6Q]<;_CE:SW9AFC-=;L\DVR!D:O<SIC:6TI&)+1E6ML)&%51K
MTDQT-Y(J&+H)CCKIP16$:;VOM@N/<U4[<35MM%+9YWH6AZ=EF0D[C8KO`$(P
M>0WD,[#8K-*.R,48N6<H`DISI%27,`!J;Q(JR_;XL+E]]W;W,DLF*NE[4CAR
M\PF-@DAYQ9UJ)3P,I$-XOS`$4D!HR8'3!/0OE'4$?$1X(KLJ@D-J!P*)!$$S
M>8!3$$_,.A#%-J&O.7PU#37@BKE?=<F#^"GN*$=0$^0-O@``E,`Z_.*JCH(:
M?A\"Z^/!%+)VX!`.WEL3YOC]'^W$`_+KRXBJ>HAIKX:!X#^G@BKC38Z_>7TO
M\NFQAR'_`$XBM8_T\$2]?>!`/\'QZ7^YN<PAK^8?W2Y!H'Y^"*Q9MP`?IWV^
MB(CXX6Q1\/CS>Q8/]6NH\$57+LM%:_Q__N!P9"44!O%4.(E$.3J#7^R'>!X>
M&O5BIP16LKGE&BX^FL=5^XSK2%E,L717'M`0>\I"6&YI5BPW$*^V54T2+(.:
M_5)!9$AA`5A;&*34PE`2*OIW+-NECQUF&>S/'L7+O'&4I(DJK+%3,<D#;EFY
M$I.*E!`!,V3DUFW4-%#:)G!02:@)?$B;1BK>+GO!E1"EXUO+6OU=.3?S(,SP
M,#(J]?)^3U:QW#YDY<'%8R8"(&$=-/#@BGRV0VK<19\:2V4=RMH`65C(@^I$
M4_BH>O&BZNQ:K.'=FE!8M&1VQ)0Y]4RKZ`1LCYHZ`;0"M,@"`;RDA[R&Y++F
MU/8#DS.6![.A5<A0%DQ8QA;"I%QLVD@PLU\AHJ5Y6$JV>,%P>1D@<A3&((EY
MN8N@@`\1^Z:FII-%*M2;,!`#A[R!]*]"_"_[O_#GO-]\VV>$/%E*5;8]11U<
MYPC(P)-'35:L.L+;)1!YU`=V8N[+OLW;;]\?X0SSE]E<L<3=(R?,R4&C1ZE!
MK+OJ]4W4K#K#*1$6S?$!L^2`XE*8`.```^'$#LVNW&6X"EJS`PDY&$?LL7L;
MXJOAD]UGNR]TFO\`%W@[35:.ZZ?4:9C*<I`0J5J-/E-[RER=*N??V=/#X:?#
MP^'YOS?HX[#UNE?+7%+#C]=GZ5%!W.NT'MR[FT)2YZX2=CPWN0P^];2^"]SF
M,Q19Y#QW*1[]*8CVCPAC((VBL-Y=N1T5FNJDHV<%\UJX;J"836JJ+6&Y7O48
M'K\9CO,F-MH.^%.#;-XZ,SU3\SVC;1?+4U2#RD)'(F-+'B^]U=.PF1`HNG$1
M)%27.43`CS"(B1-SWS=LG>OW=ZG#8EWE9MQEM)VN15AC[D_P9M>3F<Q9,OEE
MAS."P;F_YFR+"4NNM&$$DJHJW8QE<71!R(**'5,1/E(I4-A&S'&W;YVL8RVF
M8CGKA9Z!BT;+Z%-WUS%.[6^"TVF7MSXTHXA8N&C#F3?S:I$_+;)<J92@(<P#
MP10`[3.T[W.^V=O]W@YFV=V7:;G7;EO0M,G;K(VW'7#)5+ON/91:Y6.Y0+IT
ME2Z?8%K"]KCRWR#90$5R(RK4Q#F%LL4#`1'GN#=HCN$9YSSL=WY8[W(8KS7N
MSVBY;)>'N(\C,)'#&VM.K^OU^QMJABEM7(B\6Z#39.XA5"0D9UW*2DRFJ1;S
MD.G3;<$3GMY>T;NI;M-AV4]ITI>]HAKUN@8V\V9;I8)[**-;PK"3UNBI6"Q#
MA""A:&+NX5ZM4^,1:&GIURV>.'Z[AQT8D.F1,B7#M4[3-V6T3:)2-E&Z]+;3
M?\5XEQE(X]JURQ;-7Y_-W:&F9J9=O8&_TZZ5:-AFD<,',J-A7:/5.J`A2B@0
M!$1HXY2%4`FP`DIG&U?MT;SNS]E3,T=V_H7%VZ#8MG6Z*Y)-M<RKD]WAW+N`
MKH[029.5\:Y'=5VUTVVU!W'((MA;R:;)X=!JV`Z@K(J*N&*/I"89<H/S%288
M_I.]'-&7:+EW<J:G[<L;XH5EIFE[:L+Y'F<C3M]N4K%O8-O/9_RA[?IL)+5J
MLQSY9:+JT0P59FDSD>O7JXMT$2G!N5""+TQK?YVDLGWS>CB?NH=OO(U)P]OG
MQ9'(5ZXU?*3>8-A?<?1213J#5J]_=UM!Y.5>;<5IV:+-(MV[HBS8B',F19LF
MJ%4ON3J`O7=<S#5!QZ[VV8`VB6&<CE8BRYU<;C%,])TQ%VD"$E8<58QK^.*P
MZLMI03.=6)+/2,:R;.`24<E7*0R"I%V=P;MLU_>-VS+YV^X2^3-<,\H5&@\?
M9%O;^1NDHWM^,I.$G:K/7J2<*&E9\TW+012RKDH^>8'2BB9=2E)P3D?D3>>W
M]0^\5C#".`MN^=:=M"QO6=L=&C*(ZR-5,EVK)=BW(P&.*FM7,;5%K6R4>)C,
M,1DJLS8FG[`LO+R`((&*TC4U%1%,B9@][87=A>]WB)[M@3FP9"U1>-!Q*G@T
MUNSLI7!IAZ._J*I%+R&.TI4+&*\B=V5X$?Y`"`)],8@"/!$XGO<]O+?YW4L`
MP&U7'<[M/Q7BXECQYD^U6^WV3*<G>)&]UF%FVLA6(2(BZ1Z(SJ:$Q,B+9\JL
ML[=()%YT$#&'@BDHV\0N^C'&U)A0\H5W:Y.[A,;T^J4W'1Z3=\G,<47=G5H&
M$A$YRZO9BCJVFE.7XLUSF;L6LNF4_*!3:"(%(H;-@7:[[G>SGN([MM\%GM>R
M&\Q.^.WDELOX_A+'FB$<46(=7U2SBOCN2>TA^25DX"-DG+=)"0*5)^H!1,JV
MUX(B]]W;>KABKMS8+R9CJR3%.R!0M\F&K?3;;`NU&,W7;-#4?*KR,F(UVD(B
MB[:+I@)?`Q1`1*("4P@)%'EV^/O`L$W3'<7B;NB8PF(&X-XY&)F,W8UJ#>[8
MYOJ2)$VX2=VQ@@/K=8E5T@YG(1B,DT45U.DBV`WE@125O.^A]N%CMJ.1*]DF
M@2L\W*5ZSBZQM\RE*V4SM,Q>1-C#RE0:1K)X8YOP&4.@0@^(G``$>"*N;W:O
MNDKEOA8M]J^RRGVS!FWJVS\%`Y'R+:U6++,.4:\:>9$4K4<Q@'KF/Q[2Y5ND
M0KQ%%RX?/T=43JHHG52.5A'6"MR_<$!IVDLKEY2DY9[`/X"`!2D'YC5(O*4"
MZ%`I=-``/#B(WW^FR_%#^,+U[\#W^XO9O^UW#_(UU5Q^W/\`^:CBK_\`,LT?
M_0I#B$VS^J4_PG]07T3^.;_;WO'^+HO\Y06Q<_)^K^CCM/6Z5\,/4Z%SQ:KD
M."(<$0X(AP1#@B&FO\P_K#BAB9!A>L=4`QMN!!^9)5D+#E!RE/T*9O42,\./
M9.4EJ_%N7CHL*:2G8E:"<NI:*173:S!T&"Y^E!P4Y$%3"<H<V@AISVW352]<
M`D<BD=%N>HV^C4HT"8FN&)%[#DYAZ?2HO.U1B&D77;;1\GS;-ZM>\?[HMVSF
M`LZ<M*)2:S&.SIEJD,Z[*KN'K@TM6FM;<@U08N!,BB5NAY8$%(H\0VS[;0JZ
M"C4CA>,Y%_WB/H7Z)[R]RU6D\3ZK20E(T94*((Y`].))'H+F]8K:EG"W8:E%
MZ*YK$5+8UR_W-]VN!8.85M4T^M]7EU)C(5V@7C:)>LUV'LYE[0<QIF8/BKMR
MG(JGHF`I!AT=6>BU(ITZ8GICKI1)>V),86LS?W*OB/;-/NVAHZLU#Q]#9*%9
MB!A(S*D9.;\3$$,&-R=9@;==DS<)+-YRC8/'Y,RMLSI2(O($C9$H]Q#3&'K'
M+U"&D[/%K)G5/$9`L];>MTT(\B[V*)Y1UTS`<W)OZ?=-16%6="CEZ8&1!/W1
MR\QY5!;SX0VC8-.8UM<1N(A0)HP<N*Q.8UHMA'"><'D1$Q#O.RYD/;E5]R%J
MQ=B3'=8O\E3XFJ)RF7)R1=-I"1R-/T&U^I-4Z6B]EW3<8E)Y7XV*ZE_,&<@U
MY$%"B;BVCO-6MHJ6K``A,EK>=NGF`O6[N?@O:M+OFIV'2:G55*M&G4J3:+$G
MAXS^TP#62D2(Q9UC6F^S)-BI6W6?K&(:P2?S5NWR-M,GHNUVR?A&]1F<>.,I
MM#7=@F2N.Y:1BWP8N66/'ND6KQ$')$Q-SD$PY>\]1*GIR`.M4,6NY?V<J:CP
M/L>@UVX[?7U6HGH])I:>H@0`14Q1C+"^)K#(`$$@@$KN0[@<]ZFVQ:YQ2W4S
MLKNZN&T=Q#PTRZE*"29IN)4<X/<@QTRHP833Z!>8YD6:I8WRDWR<BL=LH82I
M'6-6KN]2E&9(.,5<+=`6>/N[IY,MVJZLQV26U4M:<1ZX-2M5H1I-:'Q427%@
M<%K4J\?N<RRVO6VW&MTPG%4*VYYH6?YN1AY>[IR*]%MV#D8AVS9K.8>->L9.
MJ7%G.(.4W)%B/622@$50%0IBA@GNE:GJ(1]:4)2/[H);Y"%'#P?I*VU[KNFF
MUAK:;;SI1BC?.&JJ9;1=B\"[CZ[$VQYN]RQEB>[?[VNU2CUNM;JL9Y?R%>XF
M3EI28D:ZO0H2K.F$16Y9O$HH/6O^T9E@5.F11P9$"F`I-1&T;M5EKM*8]FN]
MEO(M[4^$MEV^AOT*];4RJ;;'2&FPO-4QO&)A:;;[+0'L12Q!NI85V`K%$I^(
M8BKY$S'ODW08,C(1:\6FRT=&S8SGL@6[)F4)6Q3+56PIM)UE5W3IK"M4DR)N
MG2;9#RD4S'#:AK6TV$%GJR'*;C;SGY%JZ_P_1JZVOK:VJKU-OH[;2J5),!,B
M<3@@`"U_5<DL`Z5C(&[?(6);K@*AY5QK6*8YR\Y9PTQ;#V:Q2^-&%UD\A-ZK
M'T.,OL?63,X*V35<7),Q2%@3C4)58PQB#CJ2&-QAU.]5J5:G1H@9<J8)/.Y'
M19Z?D6EH_#VAW/1ZO5Z6I4G0ICJ"0&,P$'<QY1BLZMH[3*#C[RKE_A68Z$/R
M;P<8>.H?`<>9:\1*!C:?#7Q_/_+Q,T'JTLV7:^M<;`B$(T8VQB2/F?ZUJ\Q.
M`?I_DT_U\95>N.</T_S?Z^"(V4,!&\4Q4/ZI+97-=?`1TF66NFO@.G,'Y?#7
M@BV]7W!A1#M*9:#P$0G\`A^701#)-2_1KQ$;Y_3I?BA_$%ZN^"B=2'Q$[/*E
M#,GP^NZMW_)5[>B]5</MU0,7NH8G,H/*`XQS2!0`1'Q"@/CZ:!XAH0AA\?#0
M.(/:3$[K3C&]C^H+Z/\`QV4-9/X?]SG5B1#-T-@E_P!91L6Q;_)^K^CCM?6Z
M5\,6L9C==RKGBU50X(AP1#@B'!$."(?Z?Z:<71=^K>K9X<)Q=E82P]!Z++^H
M^J='T+GJO1?5?5O)Y/VGI?HW^:]=R_\`I]-^VYOZOCQIZK)?\[$_,_T+8IX\
MRDV%_5=FZ7^E-,V3_2-\IGWT9@;Y0^];=Y_IPY!&#]]>Y9?W]T/OH`=>K^[>
ML]4Z?QZWGY_Q\8-GX+@1W9BX5RSN_/VK;UU'BOS)WI+S+E]Z98?V;X6ZKX+.
MRS<S/:D4KH]N?S<?>A`OYGUF77V!S&S9K]:/EROOSR.H)_\`,/*]2ZSJ?\MT
MZS3_`!>(O3]S\3^3G9O$'[>',:+\UV'F4EJ_.7!3XC*X;@(XFRL7"XJN"[K8
M<6-FZSX7L9+=COZ2_>]V^5P']6]\Y*]P^T1O?L3YK=$Y^;7MX(X/8WS%\KS_
M`%;TS]]ZKSM?WCSN-P<!BJMFX<-3'V\'9Z[<F)KFY;E!ZOOG+H\;E9F&&#'@
MS<#G!B?KX?EY&>Q)(7^'5]*>&>F"*^F+YO5+Y#=`.3_,^<GO>2]H?+L6P?,+
MW)[UZ_I^E_Q.H_P^?C!INY>[*.2_=^,X.UVGY.6_H=U.:3SSYMUN4_F?A*G$
M8LMLC)Z[XNHV4W9MN:U-!SZ?:P5QM"#;JVC%\>#W,2#D0U6?9+:F#*WRPS@2
MS)U8K:/>21IL9X[Y1X>$$"A,)&34*)E5U$<.KX3%I>#;)S;;WY^?]JZ7:AOI
MKZKS%*0U_=TLAXT3#M?SS*0CA9O:#L77`%ZD?]`/RIKOIP07MGZB9;VV#,;Q
M\U?JNZQ_Z_Y(@'S6^=W-U?7<_P"_^G^9YW[EQNZKNGAI9KY.9:V)\QAZ+79N
M9<K_`.X<:<QO^%#X\&1PV*;7_E96/%A;UG:UT:,C_1CTF"??0+];UV2ODST8
MY,"ZZ^FK_.GSQKY1MXPWIO-[G]3_`'33EZGQ\OBVMW5FT\S%F94\+/V,/7=O
MN^GH6EL?F)M;W5EY+1SWP9;XORNUU<6+V7WF:UD3\<_P_/9NSCY:`Q]K]3>/
MH\]"')XO/2^F#WS[;T*$V-`Z'R.HZ_\`R;R.ET_!Y'&,]RYND;VF8,EL5[_J
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M^B^1[6`9+UOT3U/R^;\'D^;KX<3,&P]7LKB:>#K8'[1?Y5`D4?LS-/`NQ[X_
MVC9EU_[Q-=.*K*N=?LS?[NQW_M9C_P#)P1>J-'[-OU6,]*+LD]5]08^F=.?,
MWF>H=4GT/E_@\GGZKE_K?A_O>'!%9'WJ_1[]-=C^MH*@.V;K:9[D][#-A6.L
M];C_`&5U?HH#*\WKO3>1I_B\G-X:\:NLX7(/&-D.'=[WLNMO9=[[L_/_`)QT
MW^F/%><<%7)X=LW#E3S<+V-E8\7W74=^R+^!7]1-7^A@,'AN*]%M'MSV`:]C
M8O0O0W/NKD]=*##H_0_,\[G\>373QXU*'=/%1X;#Q+6-B^FQ?LOO0_\`J;R5
MJ_\`4_OGR?CT^=GX<.+/IY/9ZWM<%UC7V*<S\.G]GET_ZO+I_P"'3^;B6MQ?
/>?\`2O+W6?EQ/TO]:__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
